EVALUATION OF SAFETY USING T CELL CLONES FOR PTS WITH METASTATIC MELANOMA

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究评估T细胞输注后淋巴细胞耗竭的安全性、生存率和抗肿瘤效果。淋巴细胞清除是一种使用放射或药物（在本例中为氟达拉滨）来降低患者白细胞计数（WBC）的过程。机体对白细胞减少的反应是产生T细胞生长因子。我们假设此时注入的T细胞将通过扩大对这些生长因子作出反应，并且它们的存活将增加，从而导致抗肿瘤反应的改善。本研究的结局指标包括毒性、输注后T细胞存活、肿瘤缩小、T细胞输注后肿瘤靶向抗原表达的丧失。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The safety, survival and anti-tumor effect of infusions of T cells following lymphodepletion are evaluated in this study. Lymphodepletion is a process using radiation or drugs (in this case, fludarabine) to lower the white blood cell count (WBC) in patients. The body responds to lowered WBC by producing T cell growth factors. We hypothesize that T cells infused at this time will respond to these growth factors by expanding and their survival will increase, leading to an improved anti-tumor response. Outcome measures for this study include toxicity, T cell survival after infusion, tumor shrinkage, and loss of targeted antigen expression by the tumor after T cell infusion.